Price movement over the last 24 hours
Alcon AG vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Alcon AG trades at $66.84 (market cap $32.69B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.13. The key difference: Alcon AG pays a 0.54% dividend while Vanguard Emerging Markets Stock Index Fund ETF pays none, and Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | VWO | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | — |
52-Week High | $92.22 | $61.24 |
52-Week Low | $62.02 | $49.54 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
VWO (Vanguard FTSE Emerging Markets ETF) trades at $60.07, up 1.74% on the day, with a bullish technical signal from moving averages. The ETF maintains a low 0.06% expense ratio and a 2.4% dividend yield, positioning it as a cost-efficient emerging markets vehicle. Recent news highlights performance comparisons with competing funds and the impact of South Korea's exclusion from its index, which has contributed to underperformance relative to some peers year-to-date.
The outlook for VWO hinges on broad emerging market growth and its low-cost advantage, but faces risks from geopolitical tensions, index methodology excluding South Korea, and potential underperformance versus developed market funds. The ETF offers diversification but may lag during periods of US market strength or when specific excluded markets outperform.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →